|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found associations between single nucleotide polymorphisms at the GBA and MAPT loci and PD AAO and progression.
|
26601739 |
2016 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The MAPT H1 haplotype has been identified as a predictor of cognitive decline in Parkinson's disease (PD).
|
29899731 |
2018 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Tau protein: relevance to Parkinson's disease.
|
20678581 |
2010 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Tau protein is found to be aggregated and hyperphosphorylated (p-tau) in many neurologic disorders, including Parkinson disease (PD) and related parkinsonisms, Alzheimer disease, traumatic brain injury, and even in normal aging.
|
31085590 |
2019 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, postmortem brain samples from patients with PD and neurologically normal controls were used to evaluate whether the expression of the 3-repeat and 4-repeat isoforms of MAPT, and neighboring genes Saitohin (STH) and KIAA1267, are altered in PD cerebellum.
|
18509094 |
2008 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder.
|
29756641 |
2018 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the microtubule-associated protein tau gene (MAPT) can cause frontotemporal dementia with Parkinsonism linked to the chromosome 17, and are associated with the risk for progressive supranuclear palsy, Parkinson's disease, corticobasal degeneration, and multiple system atrophy.
|
23001634 |
2013 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study confirms the association between PD and both SNCA SNPs and the H1 MAPT haplotype.
|
21391235 |
2011 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
CTD_human |
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.
|
20711177 |
2010 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In NACP-Rep1 0/0 genotype carriers, patients without MAPT H2 haplotype had a higher rate of progression of Parkinson's disease.
|
23939307 |
2011 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
MAPT-AS1, a long non-coding RNA (lncRNA) existing at the anti-sense strand of the MAPT (microtubule associated protein tau) promoter region, was believed to regulate MAPT, which was associated with disease state in Parkinson's disease.
|
30074401 |
2019 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Common neurodegenerative proteinopathies, such as Alzheimer's disease (AD) and Parkinson's disease (PD), are characterized by the misfolding and aggregation of toxic protein species, including the amyloid beta (Aß) peptide, microtubule-associated protein Tau (Tau), and alpha-synuclein (αSyn) protein.
|
27338814 |
2016 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
GWASDB |
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.
|
22438815 |
2012 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genes involved in cytoskeletal stability and trafficking, such as MAPT and SNCA, are important risk factors for Parkinson's disease (PD).
|
27115672 |
2016 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our previous work has implicated two genetic factors in the development of cognitive dysfunction in Parkinson's disease, namely the genes for catechol-O-methyltransferase (COMT Val(158)Met) and microtubule-associated protein tau (MAPT) H1/H2.
|
19812213 |
2009 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
While MAPT has been considered a PD candidate gene and has been observed in association with PD in other GWAS, GAK is a new candidate for investigation in future studies.
|
21058943 |
2011 |
|
Parkinson Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of amyloid and tau-proteins correlate with cognitive decline and may have prognostic value for cognitive deficits in PD.
|
26991855 |
2017 |
|
Parkinson Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This work links haplotype-specific MAPT expression with a biologically functional outcome relevant for PD.
|
28689993 |
2017 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
CTD_human |
Genome-wide association study reveals genetic risk underlying Parkinson's disease.
|
19915575 |
2009 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The main goal of this work was to describe two MJD patients displaying the parkinsonian triad (tremor, bradykinesia and rigidity), namely on what concerns genetic variation in Parkinson's disease (PD) associated loci (PARK2, LRRK2, PINK1, DJ-1, SNCA, MAPT, APOE, and mtDNA tRNA(Gln) T4336C).
|
22023810 |
2011 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that H1/H2 MAPT haplotype is not a risk factor to PD in our population.
|
30339920 |
2019 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings strongly confirm SNCA and MAPT as major PD susceptibility genes for idiopathic PD in the Italian population.
|
22104010 |
2012 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
We investigated the association of Parkinson's disease (PD) with tau gene H1 haplotypes in the Norwegian population.
|
11958849 |
2002 |
|
Parkinson Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aggregation of NFTs, the abnormal hyperphosphorylation of tau protein, and the interaction between tau and alpha-synuclein may all contribute to the cell death and poor axonal transport observed in PD and Parkinsonism.
|
30333786 |
2018 |
|
Parkinson Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings add further data showing that common variants in SNCA and MAPT genes contribute to variability in progression of PD, with SNCA variants associating with motor progression while MAPT variants associated with clinical severity.
|
26776090 |
2016 |